Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL).

Autor: Candelaria M; Instituto Nacional de Cancerología México, Mexico. Electronic address: candelariahmgloria@gmail.com., Villela L; Universidad Autonoma de Sinaloa, Hospital Fernando Ocaranza ISSSTE, Mexico., Oñate-Ocana LF; Instituto Nacional de Cancerología México, Mexico., Beltran B; Instituto de Investigaciones Biomédicas, Universidad Ricardo Pala, Lima, Peru; Hostpial Edgardo Rebagliati Martins, Lima, Peru., Torres-Viera M; Clínica Santa Sofía, Instituto de Oncologia y Hematología de la Universidad Central de Venezuela, Caracas, Venezuela., Oliver A; Hospital Británico, Uruguay., Idrobo H; Junta Directiva Grupo de Estudios de Linfoproliferativos & Scientific Director in Pereira, Colombia., Perez-Jacobo F; Hospital Central Norte PEMEX, Mexico., Perini G; Hospital Israelita Albert Einstein, Sao Paolo. Brazil. Electronic address: guilherme.perini@eisntein.br., Peña C; Hospital del Salvador, Santiago de Chile. Chile., Korin L; Instituto Alexander Fleming, Argentina., Castro D; Hospital Nacional Edgardo Rabagliati Martíns, Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porras, Lima, Peru., Irigoyen V; Hospital Casmu y Hospital Cosem, Uruguay., Paredes S; Hospital Nacional Edgardo Rabagliati Martíns, Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porras, Lima, Peru., Hernandez-Hernandez JA; Escuela de Medicina y Ciencias de la Salud, TEC de Monterrey, Mexico. Electronic address: j.a.hernandez@tec.mx., Colunga P; Hospital Universitario de Neuvo León, Universidad Autónoma de Nuevo León. Mexico., Gomez-Almaguer D; Hospital Universitario de Nuevo León, Mexico., Ruiz-Argüelles G; Clínica Ruiz, Puebla, Mexico. Electronic address: jruiz1@hsctmexico.com., Otañez M; Hospital de Alta Especialidad de Sonora, Mexico., Castillo JJ; Division of Hematological Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: jorgej_castillo@dfci.harvard.edu., Malpica L; Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: lemalpica@mdanderson.org.
Jazyk: angličtina
Zdroj: Journal of geriatric oncology [J Geriatr Oncol] 2024 Nov 29; Vol. 16 (1), pp. 102160. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.1016/j.jgo.2024.102160
Abstrakt: Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma, predominantly afflicting older adults. There remains a notable absence of data regarding DLBCL in older adults in Latin America.
Materials and Methods: We conducted a retrospective analysis of 608 newly diagnosed Latin American patients with DLBCL aged ≥65 years.
Results: The median age at diagnosis was 74 years (range: 65-96 years), 51 % were female, 36 % had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, and 65 % had advanced disease. The most common regimens used were standard-dose R-CHOP (n = 420, 69 %), R-CVP (n = 77, 12 %), R-mini-CHOP (n = 74, 12 %), and CHOP/CVP (n = 30, 5 %). With a median follow-up of 60 months (95 % confidence interval [CI]: 38.7-75.2 months), the five-year overall survival (OS) rate was 50 % (95 % CI, 43-58). An ECOG PS ≥2 (hazard ratio [HR] 1.93; 95 % CI 1.51-2.46; p < 0.01), advanced clinical stage (HR 1.46; 95 % CI 1.12-1.91; p < 0.01), increased serum lactic dehydrogenase level (HR 1.48; 95 % CI 1.16-1.87; p < 0.01), and albumin level < 3.5 mg/dL (HR 1.64; 95 % CI 1.29-2.10; p < 0.01) were associated with an inferior OS. Using anthracyclines (HR 0.50; 95 % CI 0.38-0.66; p < 0.01) and using rituximab (HR 0.51; 95 % CI 0.36-0.73; p < 0.01) were independently associated with a superior OS.
Discussion: In a large cohort of Latin American older patients with DLBCL, therapy and outcome patterns are similar to those reported internationally. The lack of standardized geriatric assessments in Latin America represents an essential area for research to better stratify older patients with DLBCL deemed to be at higher risk for toxicity.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: